Deferoxamine mesylate [138-14-7]
Référence B6068-100mg
Conditionnement : 100mg
Marque : APExBIO Technology
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Deferoxamine mesylate
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Deferoxamine mesylate is a specific iron-chelating agent [1][2][3]
Deferoxamine mesylate can be used for treating acute iron intoxication. Deferoxamine complexed with iron to form ferrioxamine and then prevented the iron from entering into further chemical reactions. The formed chelate is readily soluble in water and passes easily through the kidney [1].
In Fisher rats transplanted with the 13762NF mammary adenocarcinoma, deferoxamine mesylate reduced rat tumor growth. While deferoxamine mesylate?injections plus a low iron diet caused the greatest inhibitory effect on tumor growth. Deferoxamine mesylate may be a useful chemotherapeutic agent in the treatment of breast cancer [2]. In Sprague-Dawley rats, injected with deferoxamine mesylate (75-90 mg; 300 mg/kg) via the celiac artery before surgery. Deferoxamine mesylate signi?cantly lowered the serum levels of amylase, lipase, and malondialdehyde (MDA) after orthotopic liver autotransplantation. Deferoxamine mesylate also protected pancreatic tissue through up-regulated expression of HIF-1 protein and inhibition of oxidative toxic reactions [3].
References:
Deferoxamine mesylate (Desferal mesylate). A specific iron-chelating agent for treating acute iron intoxication. Clin Pharmacol Ther. 1969 Jul-Aug;10(4):595-6.
Wang F, Elliott RL, Head JF. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 1999 Jan-Feb;19(1A):445-50.
Li Y, Zhang PJ, Jin C, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplant Proc. 2011 Jun;43(5):1450-5.
- 1. Wei Huang, Gaowen Qu, et al. "Kallistatin enhances the phagocytic function of macrophages by decreasing the expression of CD24 in gastric cancer cells via the HIF-1α signaling pathway." bioRxiv. 05 Apr, 2024.
- 2. Hao Zheng, Jinming Liu, et al. "Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance." Nat Cancer. 2024 Jan 30. PMID: 38291304
- 3. Qianping Zhang, Tiantian Sun, et al. "PAFAH2 suppresses synchronized ferroptosis to ameliorate acute kidney injury." Nat Chem Biol. 2024 Jan 29. PMID: 38287154
- 4. Zhijing He, He Zhou, et al. "A bimetallic dual-targeting nanoplatform for combinational ferroptosis activation/epigenetic regulation/photothermal therapy against breast cancer and tumor microenvironment remodeling." Chemical Engineering Journal Volume 479, 1 January 2024, 147466.
- 5. Mingchao Mu, Qin Zhang, et al. "3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis." Cancer Gene Ther. 2023 Aug 9. PMID: 37558749
- 6. Yu Zhang, Xiyou Du, et al. "A Vanadium-Based Nanoplatform Synergizing Ferroptotic-like Therapy with Glucose Metabolism Intervention for Enhanced Cancer Cell Death and Antitumor Immunity." ACS Nano. 2023 Jun 5. PMID: 37272777
- 7. Fan Yu, Qianping Zhang, et al. "Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis." Cell Discov. 2022 May 3;8(1):40. PMID: 35504898
- 8. Binghua Liu, Weiyan Wang, et al. "Sodium iodate induces ferroptosis in human retinal pigment epithelium ARPE-19 cells." Cell Death Dis. 2021 Mar 3;12(3):230. PMID: 33658488
- 9. Junhong Zhang, Ni Wang, et al. "Oridonin induces ferroptosis by inhibiting gamma‐glutamyl cycle in TE1 cells." Phytother Res 2020 Aug 31. PMID: 32869425
- 10. Tianshu Wu, Xue Liang, et al. "Induction of ferroptosis in response to graphene quantum dots through mitochondrial oxidative stress in microglia." Part Fibre Toxicol. 2020 Jul 11;17(1):30. PMID: 32652997
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 656.79 |
| Cas No. | 138-14-7 |
| Formula | C26H52N6O11S |
| Solubility | ≥65.7 mg/mL in H2O; insoluble in EtOH; ≥29.8 mg/mL in DMSO |
| Chemical Name | (Z)-4-((5-aminopentyl)(hydroxy)amino)-N-(5-((Z)-N,4-dihydroxy-4-((5-(N-hydroxyacetamido)pentyl)imino)butanamido)pentyl)-4-oxobutanimidic acid compound with methanesulfonic acid (1:1) |
| SDF | Download SDF |
| Canonical SMILES | CC(N(O)CCCCC/N=C(O)/CCC(N(O)CCCCC/N=C(O)/CCC(N(O)CCCCCN)=O)=O)=O.CS(O)(=O)=O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
| Cell lines | Adipose derived mesenchymal stem cells (AdMSCs) |
| Reaction Conditions | 30, 60 or 120 μM deferoxamine mesylate for 12 h inubation |
| Applications | Cells exposed to 30 or 60 μM of deferoxamine mesylate showed significantly lower expression of hypoxia-inducible factor-1α (HIF-1α) when compared with cells cultured under 1% O2, but cell treated with 120 μM deferoxamine mesylate was able to mimic cells under hypoxic conditions. Deferoxamine mesylate could promote wound healing in AdMSCs through HIF-1α stabilization. |
| Animal experiment:[2] | |
| Animal models | Sprague-Dawley rats, 0.25 ~ 0.30 kg |
| Dosage form | 75 ~ 90 mg; 300 mg/kg Injected via the celiac artery at 24 and 48 hours before orthotopic liver autotransplantation |
| Applications | Deferoxamine mesylate significantly lowered the serum levels of amylase, lipase, and malondialdehyde after orthotopic liver autotransplantation. Deferoxamine mesylate also protected pancreatic tissue through up-regulated expression of HIF-1α protein and inhibition of oxidative toxic reactions. |
| Note | The technical data provided above is for reference only. |
| References: 1. Wahl EA, Schenck TL, Machens HG, et al. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Scientific Reports, 2016, 6: 36879. 2. Li Y, Zhang PJ, Jin C, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplantation Proceedings, 2011, 43(5): 1450-1455. | |